These powerful drugs have many serious side effects such as kidney failure.

Currently, people with severe uveitis take steroids or other drugs that the inflammation to control the inflammation.Unfortunately, these powerful drugs have many serious side effects such as kidney failure, glaucoma, osteoporosis, increased blood sugar, elevated blood pressure and weight gain.Because their immune systems are compromised, patients must also contact with other people contact with other people, of four years. Infectious diseases. Obviously, current therapies for uveitis greatly reduces a patient’s quality of life.

The National Eye Institute conducts and supports research that leads eyesight treatments and plays a key role in reducing visual impairment and blindness. The NEI is part of the National Institutes of Health , an agency of the U.S. Department of Health and Human Services.

Trial in the U.S.nounces successful completion Rhitol Phase II clinical trialoncology focused biopharmaceutical product development company Kiadis Pharma announced that it has successfully completed its Rhitol Phase II trial with the last patient’s completion of the 6 months of treatment completed.Courtesy you , the total Kaiser Daily Health Policy Report show, Jearch the archives , or sign up for email service to Imperial Daily Health policy coverage from strongly committed emperor network. A free service of of The Henry J. Published. Kaiser Family foundatio 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Srivastava the company is added that it could take three to four years until an final decision on the patents (Reuters.. PUBPAT Executive Director of Dan Ravicher being is ‘very satisfied’to the Patent Office shall a decision. Ravicher added that at any HIV-positive person ‘to be for best drug, without any undeserved patents makes it exorbitantly expensive items.’.

Gilead has a right to respond to the PTO decision . Patents are protected while Gilead responded on the be ruling, the / / CNNMoney.com report (AP / CNNMoney. Amy Flood, a spokesman for Gilead HIV-positive person which is a ‘typical pace in the re-examination process ‘adding even though ‘process might take some time to complete, ‘the company did not ‘believe that exclusivity of our products is at risk ‘(Reuters.

The majority of of Gilead income comes from sale of anti-retroviral drugs, the Reg.